Related Experiment Video

Updated: Jun 13, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis

Graeme Jones1

  • 1Musculoskeletal Unit, Menzies Research Institute, Private bag 23, Hobart Tasmania 7001, Australia. g.jones@utas.edu.au

Expert Review of Clinical Immunology
|April 21, 2010
PubMed

Insights

Tocilizumab (TCZ) is a novel biologic therapy for inflammatory arthritis, demonstrating superiority over methotrexate in clinical outcomes. This interleukin-6 receptor inhibitor shows a rapid onset of action and supports its use as a first-line treatment.

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Inflammatory arthritis treatment has advanced with targeted therapies.
  • Tocilizumab (TCZ), an interleukin-6 (IL-6) receptor inhibitor, has emerged as a significant therapeutic option.

Purpose of the Study:

  • To evaluate the efficacy and safety of tocilizumab (TCZ) monotherapy compared to methotrexate monotherapy in patients with inflammatory arthritis.
  • To assess TCZ's role as a potential first-line biologic therapy.

Main Methods:

  • The Actemra Versus Methotrexate Double-blind Investigative Trial in Monotherapy (AMBITION) trial compared TCZ (8 mg/kg every 4 weeks) with methotrexate monotherapy over 24 weeks.
  • Clinical outcomes measures were used to assess treatment effectiveness.

Main Results:

  • Tocilizumab (TCZ) demonstrated superiority over methotrexate across multiple clinical outcomes with a rapid onset of effect.
  • While liver toxicity was less frequent with TCZ, increased lipids, decreased neutrophils, and skin infections were more common.

Conclusions:

  • The AMBITION trial supports tocilizumab (TCZ) as an effective monotherapy for inflammatory arthritis.
  • TCZ is suggested as a first-line biologic therapy option based on its efficacy and safety profile.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...